Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Not just research tools—proteasome inhibitors offer therapeutic promise

Nature Medicine volume 8, pages 338–340 (2002)Cite this article

A Corrigendum to this article was published on 01 June 2002

Proteasome inhibitors have served as critical tools to investigate protein degradation in eukaryotic cells. Now, these inhibitors are proving effective in the treatment of cancer and inflammatory disorders, most recently in animal models of psoriasis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The 26S proteasome.

Baumeister et al. (1998) Cell 92: 367–380

References

  1. Etlinger, J. & Goldberg, A. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc. Natl. Acad. Sci. USA 74, 54–58 (1977).

    Article  CAS  Google Scholar 

  2. Hershko, A. & Ciechanover, A. The ubiquitin system. Ann. Rev. Biochem. 67, 425–479 (1998).

    Article  CAS  Google Scholar 

  3. Voges, D., Zwickl, P. & Baumeister, W. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68, 1015–1068 (1999).

    Article  CAS  Google Scholar 

  4. Kisselev, A.F. & Goldberg, A.L. Proteasome inhibitors: from research tools to drug candidates. Chem. Biol. 8, 739–758 (2001).

    Article  CAS  Google Scholar 

  5. Zollner, T.M. et al. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 109, 671–679 (2002).

    Article  CAS  Google Scholar 

  6. Adams, J. Proteasome inhibition in cancer: development of PS-341. Semin Oncol. 28, 613–619 (2001).

    Article  CAS  Google Scholar 

  7. Rock, K.L. et al. Inhibitors of the proteasome block nonlysosomal protein degradation and the generation of peptides presented on MHC-class I molecules. Cell 78, 761–771 (1994).

    Article  CAS  Google Scholar 

  8. Palombella, V., Rando, O., Goldberg, A. & Maniatis, T. The ubiquitin-proteasome pathway is required for processing the NF-κB precursor protein and the activation of NF-κB. Cell 78, 773–785 (1994).

    Article  CAS  Google Scholar 

  9. Rock, K.L. & Goldberg, A.L. Degradation of cell proteins and the generation of MHC class I- presented peptides. Annu. Rev. Immunol. 17, 739–779 (1999).

    Article  CAS  Google Scholar 

  10. Barnes, P.J. & Karin, M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336, 1066–1071 (1997).

    Article  CAS  Google Scholar 

  11. Silverman, N. & Maniatis, T. NF-κB signaling pathways in mammalian and insect innate immunity. Genes Dev. 15, 2321–2342 (2001).

    Article  CAS  Google Scholar 

  12. Palombella, V.J. et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95, 15671–15676 (1998).

    Article  CAS  Google Scholar 

  13. Elliott, P.J., Pien, C.S., McCormack, T.A., Chapman, I.D. & Adams, J. Proteasome inhibition: A novel mechanism to combat asthma. J. Allergy Clin. Immunol. 104, 294–300 (1999).

    Article  CAS  Google Scholar 

  14. Vanderlugt, C.L., Rahbe, S.M., Elliott, P.J., Dal Canto, M.C. & Miller, S.D. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J. Autoimmun. 14, 205–211 (2000).

    Article  CAS  Google Scholar 

  15. Phillips, J.B., Williams, A.J., Adams, J., Elliott, P.J. & Tortella, F.C. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 31, 1686–1693 (2000).

    Article  CAS  Google Scholar 

  16. Hideshima, T. et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071–3076 (2001).

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology Harvard Medical School, Boston, Massachusetts, USA

    Alfred L. Goldberg

  2. Department of Pathology University of Massachusetts Medical Center, Worcester, Massachusetts, USA

    Kenneth Rock

Authors
  1. Alfred L. Goldberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Rock
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goldberg, A., Rock, K. Not just research tools—proteasome inhibitors offer therapeutic promise. Nat Med 8, 338–340 (2002). https://doi.org/10.1038/nm0402-338

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0402-338

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing